Minerva Neurosciences, Inc. (NERV) stock intrinsic value fair value estimate & owner earnings analysis

Minerva Neurosciences is a clinical-stage drug developer with no approved products and no revenue. Its lead candidate, roluperidone, targets negative symptoms of schizophrenia. The FDA issued a Complete Response Letter on the roluperidone application on February 26, 2024. The company is now running a confirmatory Phase 3 trial, with topline efficacy results expected in the second half of 2027 and relapse data in the second half of 2028. It also holds a contingent claim tied to seltorexant, a depression and insomnia drug developed with Janssen (Johnson & Johnson). In 2021 Minerva sold its seltorexant royalty to Royalty Pharma for $60 million and kept the right to up to $95 million of milestone payments, which depend on Janssen completing Phase 3 trials and winning regulatory approvals. How we measure it: we value a business on the cash it generates for owners after stock compensation and necessary investment. Minerva has consumed cash every year we could measure. Owner earnings were negative each year from 2019 to 2025, from about -$10.79 per share in 2019 to about -$1.75 per share in 2025. Cash used in operations was $13.5 million in 2025. Per-share figures are adjusted for the later reverse stock split. Working-capital movements and capital spending were not separately available in the structured data and are treated as zero, which does not change the conclusion because the earnings are negative on cash used and stock compensation alone. Reported 2025 net loss was $293.4 million, far larger than cash used, so we rely on the cash figure. Bear, base and bull cases: we assign $0 per share to all three. Every possible source of future value depends on something that has not yet happened: FDA approval of roluperidone after a trial that has not read out, or Janssen finishing Phase 3 and gaining approval for seltorexant so the milestones are paid. Approval, launch success and milestone triggers are not secured, contracted or the output of a repeatable process, so none is credited. We also credit no value for the cash on hand ($82.4 million at December 31, 2025, and an October 2025 private placement of up to $200 million of which $80 million was received up front) because that money is committed to funding the trial and operating costs, which the model shows as continuing losses, and it would be double-counting to add it to a business that consumes it. In the bear case the trial fails or is delayed, the money is spent, and the shares are worth nothing. Share count has also risen sharply (weighted diluted shares were about 8.5 million in 2025 and about 79 million in the second quarter of 2026), so each share's claim on any eventual success is smaller. What would make this wrong: a positive Phase 3 result in 2027 followed by an approval, or milestone payments from Janssen's seltorexant program, would create value the model does not include. Those outcomes are possible but not yet evidenced, so the valuation would be revisited once one of them occurs. Management believes cash is sufficient for at least twelve months from the date of the 2025 financial statements. The 2025 annual report also notes that Nasdaq had a one-year monitoring period, ending March 17, 2026, over the company's continued listing. Margin-of-safety price: $0. There is no earnings stream that can support a price today.